Ublituximab, sold under the brand name Briumvi, is an immunomodulator used for the treatment of multiple sclerosis. It is a CD20-directed cytolytic monoclonal...
10 KB (602 words) - 04:53, 8 February 2024
with adverse effects that may influence their risk to benefit profiles. Ublituximab was approved for medical use in the United States in December 2022. Overview...
170 KB (18,091 words) - 21:07, 14 September 2024
ocrelizumab, obinutuzumab, ofatumumab, ibritumomab tiuxetan, tositumomab, and ublituximab, which are all active agents in the treatment of all B cell lymphomas...
26 KB (2,953 words) - 22:19, 25 June 2024
humanized EpCAM cancer Tuvirumab human hepatitis B virus chronic hepatitis B Ublituximab Briumvi mab chimeric CD20 Y multiple sclerosis, chronic lymphocytic leukemia...
136 KB (4,020 words) - 07:14, 15 August 2024
L04AG11 Anifrolumab L04AG12 Ofatumumab L04AG13 Teprotumumab L04AG14 Ublituximab L04AG15 Divozilimab L04AG16 Rozanolixizumab L04AH01 Sirolimus L04AH02...
3 KB (367 words) - 15:37, 25 January 2024
CD20 Obinutuzumab Ocrelizumab (+hyaluronidase) Pascolizumab Rituximab Ublituximab CD23 Gomiliximab Lumiliximab CD40 Teneliximab Toralizumab CD62L/L-selectin...
7 KB (299 words) - 13:45, 27 April 2024
U-Cort U-Gencin ubenimex (INN) ubidecarenone (INN) ubisindine (INN) ublituximab (INN) Ucedane Ucephan udenafil (INN, USAN) ufenamate (INN) ufiprazole...
4 KB (291 words) - 04:50, 2 July 2024
CD20 Obinutuzumab Ocrelizumab (+hyaluronidase) Pascolizumab Rituximab Ublituximab CD23 Gomiliximab Lumiliximab CD40 Teneliximab Toralizumab CD62L/L-selectin...
38 KB (2,656 words) - 12:11, 30 October 2023
Hartung, H. P., Alvarez, E., Qian, P., Wray, S., ... & Cree, B. A. (2022). Ublituximab versus teriflunomide in relapsing multiple sclerosis. New England Journal...
16 KB (1,512 words) - 05:10, 3 September 2024
molecule anti-cancer drugs (e.g. venetoclax, atezolizumab, duvelisib, ublituximab, zanubrutinib, obinutuzumab, olatuzumab, and blinatumomab) which are...
37 KB (4,783 words) - 14:57, 23 February 2024
lymphocytic leukemia (SLL) which utilized umbralisib in tandem with ublituximab, known as the "U2" regimen. The decision was based on the overall survival...
19 KB (1,275 words) - 15:40, 30 January 2024
monoclonal antibodies: natalizumab, alemtuzumab, ocrelizumab, ofatumumab, and ublituximab; and immunomodulators: glatiramer acetate, mitoxantrone, fingolimod,...
131 KB (14,018 words) - 08:00, 24 June 2024
tesirine Margetuximab Mirvetuximab soravtansine Rituximab# Siltuximab Ublituximab Zolbetuximab Humanized Abituzumab§ Alemtuzumab Axatilimab Belantamab...
5 KB (368 words) - 15:29, 21 August 2024
(PPMS) Ofatumumab (Kesimpta) is another anti-CD20 monoclonal antibody. Ublituximab (Briumvi) was approved for medical use in the United States in December...
83 KB (9,405 words) - 11:49, 23 August 2024
tesirine Margetuximab Mirvetuximab soravtansine Rituximab# Siltuximab Ublituximab Zolbetuximab Humanized Abituzumab§ Alemtuzumab Axatilimab Belantamab...
4 KB (241 words) - 13:42, 14 July 2024
tesirine Margetuximab Mirvetuximab soravtansine Rituximab# Siltuximab Ublituximab Zolbetuximab Humanized Abituzumab§ Alemtuzumab Axatilimab Belantamab...
3 KB (129 words) - 01:04, 19 July 2023